GOV.UK
Guidance
The Yellow Card Scheme: guidance for healthcare professionals
Details of the Yellow Card Scheme, which is the system for recording adverse incidents with medicines and medical devices in the UK.
Overview
The Yellow Card Scheme is vital in helping the Medicines and Healthcare products Regulatory Agency (MHRA) monitor the safety of all healthcare products in the UK to ensure they are acceptably safe for patients and users.
Reports can be made for:
- suspected adverse drug reactions (ADRs) to all medicines including:
- vaccines
- blood factors and immunoglobulins
- herbal medicines
- homeopathic remedies
- all medical devices available on the UK market
- defective medicines (those that are not of an acceptable quality)
- fake or counterfeit medicines or medical devices
- nicotine-containing electronic cigarettes and refill containers (e-liquids)
It is important that problems with medicines and medical devices and other nicotine e-cigarette products are reported, as the reports help identify new problems with these products.
MHRA will review the product and if necessary and take action to minimise risk and maximise benefit to patients and the public.
MHRA is also able to investigate counterfeit medicines or devices and if necessary take action.
What to report
Medicines
For established medicines and vaccines you should report all serious suspected ADRs, even if the effect is well recognised.
We are particularly interested in receiving Yellow Card reports of suspected ADRs:
- in children
- in patients that are over 65
- to biological medicines and vaccines
- associated with delayed drug effects and interactions
- to complementary remedies such as homeopathic and herbal products
See .
See .
You do not have to prove causality to report a suspected ADR, only a suspicion is needed.
Black triangle scheme
New medicines and vaccines that are under additional monitoring have an inverted black triangle symbol (▼) displayed in their package leaflet and summary of product characteristic, together with a short sentence explaining what the triangle means – it does not mean the medicine is unsafe. You should report all suspected ADRs for these products.
The European Medicines Agency (EMA) is responsible for maintaining the list of black triangle products.
This symbol appears next to the name of a relevant product:
- in the British National Formulary (BNF)
- in the British National Formulary for Children (BNFC)
- in Monthly Index of Medical Specialties (MIMS)
- in the Association of the British Pharmaceutical Industry (ABPI) Medicines Compendium
- on advertising material
- in Drug Safety Update
- in summaries of product characteristics and patient information leaflets
See .
Medical devices
Any adverse incident involving a medical device should be reported.
If a device has been involved in an incident, do not throw it away or repair it if possible. If the police or coroner is involved in the investigation hold onto the device until MHRA contacts you. Otherwise you can make the device available to the manufacturer for analysis.
Do not send medical devices to MHRA unless we specifically ask you.
E-cigarettes and e-liquids
Any adverse incident involving a nicotine e-cigarette or refill container (e-liquid) should be reported. MHRA works with local Trading Standards bodies to ensure the safety of these products.
How to report
You can report through the Yellow Card website.
For medicines, in some cases you can report using your clinical IT systems, such as the MiDatabank system and SystmOne.
You can send medicines Yellow Card reports by post. Forms are available:
- by .
- by writing to FREEPOST YELLOW CARD (no other address details necessary)
- by emailing yellowcard@mhra.gsi.gov.uk
If you want to report an incident with a medical device in Northern Ireland you should report it to the Northern Ireland Adverse Incident Centre (NIAIC).
If you want to report an incident with a medical device in Scotland you should report it to Health Facilities Scotland unless you are a private facility providing care to private clients, in which case you should report to MHRA and the Care Inspectorate.
Interactive Drug Analysis Profiles (iDAPs)
Interactive listings of all suspected ADRs reported by healthcare professionals and members of the public for a particular drug substance (formally called drug analysis prints) are available to view.
Further guidance and online learning
New e-learning module for doctors
We have created a new free e-learning module for doctors to learn about the importance of reporting suspected adverse drug reactions (ADRs).
The European Accreditation Council for Continuing Medical Education (EACCME), part of the European Union of Medical Specialists (UEMS), has given the module the highest order of accreditation. Doctors are awarded 1 EACCME credit (1 hour CPD) on completion of the 45 minute ADR e-learning module.
‘Adverse Drug Reactions: reporting makes medicines safer’
The module was developed as part of the SCOPE Joint Action project to raise awareness levels of ADR reporting.
Please complete this short survey upon completion of the free e-learning.
E-learning modules for pharmacists
The Centre for Postgraduate Pharmacy Education (CPPE) has developed a series of 3 e-learning programmes with the Wales Centre for Pharmacy Professional Education and MHRA. The programme has been endorsed by the Drug Safety Research Unit.
The e-learning modules should help pharmacists understand how to identify, report and prevent ADRS.
Adverse drug reactions and medicines safety
Reporting adverse drug reactions
Patients and adverse drug reactions
E-learning module for nurses
The Nursing Times, in close collaboration with MHRA, have developed an e-learning module for nurses.
The module is free once you have registered and counts for 2 hours continuing professional development (CPD) credits.
Published 23 January 2015
Last updated 8 November 2017 + show all updates
Last updated 8 November 2017 + show all updates
- Updated survey link
- Information about new e-learning modules for doctors.
- New .pdf attachment for 'Contribution of Yellow Cards to identifying safety issues'.
- Updated Medical devices information.
- Updated to include reference to reporting issues with nicotine-containing electronic cigarettes and refill containers (e-liquids).
- Drug analysis prints renamed to Interactive Drug Analysis Profiles.
- First published.